The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) ...

湿疹和特应性皮炎（atopic dermatitis，AD）是一种常见的慢性复发皮肤疾病，与个人或家族特应性病史（如哮喘、过敏性鼻炎）密切相关。目前特应性皮炎的发病率在儿童中约为10%～30%，在成人中约为2%～10%，并且在过去几十年增加了两到三倍 ...

While the condition can impact quality of life and mental health, seeking treatment and support can make a powerful ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

总而言之，通过建设县域AD达标门诊可以极大地缓解当前存在的种种问题，让千万像小李这样的患者重获新生。同时，这也标志着我国向着实现‘健康中国2030’目标迈出了坚实的一步。让我们一起期待，在不久的将来，无论身居何方，每个人都能享受到高质量医疗服务的美好愿景吧！ 返回搜狐，查看更多 ...

As Delhi’s AQI hits a new high, it is essential to know the effect it can have on our skin. Know the preventive measures from ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

CRANBURY, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MJH Life Sciences ®, a premier provider of health care events, media, and education, today announced the acquisition of the Revolutionizing Atopic ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

ENS-002 leverages a carefully selected trio of microbes to subdue virulent, inflammation-causing S. aureus, a core microbial driver of atopic dermatitis, offering a potential novel avenue for ...